1800-272-662
Shopping Cart 0
countryflagAU
Login

Nova EYE Medical Ltd

Healthcare AU EYE

0.15AUD
-(-%)

Last update at 2026-03-13T04:48:00Z

Day Range

0.140.15
LowHigh

52 Week Range

0.090.20
LowHigh

Fundamentals

  • Previous Close 0.15
  • Market Cap42.73M
  • Volume98523
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.88300M
  • Revenue TTM33.05M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM 22.05M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -9.05900M -8.79000M -17.00200M -8.24600M -5.25000M
Minority interest - - - - -
Net income -9.05900M -8.79000M -15.29300M -7.49600M -4.35600M
Selling general administrative 1.85M 11.78M 11.26M 10.04M 7.87M
Selling and marketing expenses 17.77M 3.04M 3.20M 1.77M 0.73M
Gross profit 20.07M 20.19M 14.61M 11.34M 11.15M
Reconciled depreciation 2.26M 2.99M 2.30M 1.81M 1.51M
Ebit -11.24600M -8.96800M -5.73500M -9.69900M -5.24500M
Ebitda -8.98500M -5.97900M -3.43800M -7.88800M -3.73000M
Depreciation and amortization 2.26M 2.99M 2.30M 1.81M 1.51M
Non operating income net other - - - - -
Operating income -11.24600M -8.96800M -11.77900M -9.69900M -4.96500M
Other operating expenses 40.51M 32.29M -28.81400M -16.58700M -14.32900M
Interest expense 0.16M 0.07M - 0.03M 0.00500M
Tax provision 0.00000M 0.00000M -1.70900M -0.75000M -0.89400M
Interest income 0.08M 0.12M 0.08M 0.03M 0.55M
Net interest income -0.07400M 0.05M 0.05M -0.03000M 0.17M
Extraordinary items - - - - 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense - -5.17100M -1.70900M -0.75000M -0.89400M
Total revenue 29.27M 23.32M 17.24M 13.63M 13.39M
Total operating expenses 31.31M 14.39M 26.39M 21.04M 16.32M
Cost of revenue 9.20M 3.13M 2.63M 2.29M 2.24M
Total other income expense net 2.19M 0.18M -5.27200M 1.48M -0.25400M
Discontinued operations - - - - -
Net income from continuing ops -9.05900M -8.79000M -15.29300M -7.49600M -4.35600M
Net income applicable to common shares -9.05900M -8.79000M -15.29300M -7.49600M -4.35600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 26.50M 29.88M 30.36M 36.62M 41.99M
Intangible assets 6.86M - 8.45M 7.17M 3.44M
Earning assets - - - - -
Other current assets - 0.23M 1.15M 1.85M 1.60M
Total liab 7.54M 8.55M 7.17M 6.23M 6.66M
Total stockholder equity 18.97M 21.33M 23.19M 30.40M 35.34M
Deferred long term liab - - 4.87M 10.85M 8.65M
Other current liab - 1.64M 1.96M 1.46M 2.68M
Common stock - 52.71M 45.17M 37.44M 36.68M
Capital stock 58.94M - 45.17M 37.44M 36.68M
Retained earnings -39.74600M -30.68700M -21.89700M -6.60400M 0.89M
Other liab - - - 0.97M 0.21M
Good will - - - - -
Other assets - - 4.94M 10.92M 8.72M
Cash 5.05M 6.15M 7.42M 8.00M 17.80M
Cash and equivalents - - 7.42M 8.00M 17.80M
Total current liabilities 5.15M 5.68M 6.27M 3.86M 4.69M
Current deferred revenue - - -0.63900M -0.54400M -1.93800M
Net debt - -2.80200M -5.88800M -6.05700M -14.10300M
Short term debt - 0.48M 0.64M 0.54M 1.94M
Short long term debt - - - - 1.42M
Short long term debt total - 3.35M 1.53M 1.94M 3.70M
Other stockholder equity - - -23.27800M -30.83600M -37.57000M
Property plant equipment - - 2.36M 2.94M 3.51M
Total current assets 12.33M 14.75M 14.60M 15.59M 26.33M
Long term investments - - - - -
Net tangible assets - - 14.74M 23.22M 31.89M
Short term investments - - - - -
Net receivables 4.11M 4.08M 2.22M 2.20M 4.02M
Long term debt - - 0.89M - -
Inventory 2.81M 4.28M 3.81M 3.54M 2.90M
Accounts payable 2.35M 3.57M 4.31M 2.41M 2.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.69300M -0.08700M -0.43900M -2.23500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 11.16M 0.07M 0.07M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 14.18M 15.13M 15.76M 21.04M 15.67M
Capital lease obligations 3.02M - 1.53M 1.94M 2.28M
Long term debt total - - 0.89M 1.40M 1.76M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.36400M -0.32500M -0.69700M -4.54100M -2.98000M
Change to liabilities - - -0.43300M 0.54M -1.82300M
Total cashflows from investing activities -0.36400M -0.32500M -0.69700M -4.54100M -2.98000M
Net borrowings - - -0.65300M -0.40200M -0.58200M
Total cash from financing activities 5.56M 6.91M 6.82M -0.40200M -61.61200M
Change to operating activities - - 0.21M 0.00600M 1.43M
Net income -9.05900M -8.79000M -15.29300M -7.49600M -4.35600M
Change in cash -1.09600M -1.26800M -0.58100M -9.80100M -77.84800M
Begin period cash flow 6.15M 7.42M 8.00M 17.80M 95.65M
End period cash flow 5.05M 6.15M 7.42M 8.00M 17.80M
Total cash from operating activities -6.15000M -7.85700M -6.82400M -4.71800M -13.14400M
Issuance of capital stock 6.17M 7.43M 7.47M - -
Depreciation - 2.99M 2.30M 1.81M 1.51M
Other cashflows from investing activities -0.06600M -0.11400M -0.13000M -0.96500M 0.24M
Dividends paid - - - 0.00000M -19.38600M
Change to inventory 0.29M -0.47700M -0.26600M -0.63900M 0.03M
Change to account receivables -0.10300M -1.86100M -0.00200M 1.82M -1.61600M
Sale purchase of stock 6.17M 7.43M 7.47M 0.00000M -41.64400M
Other cashflows from financing activities - -0.51800M -0.65300M -0.40200M -0.58200M
Change to netincome - - 5.98M -1.42200M -0.66500M
Capital expenditures 0.43M 0.45M 0.80M 5.59M 2.23M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.53300M -2.05700M -0.26800M 1.18M -1.58300M
Stock based compensation - 0.04M 0.18M 0.20M -
Other non cash items -5.61700M 0.00100M 6.17M 0.97M -8.72000M
Free cash flow -6.57600M -8.30600M -7.62400M -10.30900M -15.37200M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EYE
Nova EYE Medical Ltd		 - -% 0.15 - 70.92 1.29 2.70 1.30 -3.9647
COH
Cochlear Ltd		 -4.74 2.65% 174.42 33.10 26.39 4.88 6.04 5.59 23.13
4DX
4DMEDICAL Ltd		 -0.15 3.55% 4.07 - - 401.92 37.59 417.71 -7.2899
AVR
Anteris Technologies Global Corp		 - -% 9.10 - - 475.96 166.77 334.65 -5.1986
PNV
Polynovo Ltd		 - -% 0.94 94.00 30.21 4.66 7.81 4.68 93.96

Reports Covered

Stock Research & News

View All

Profile

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Nova EYE Medical Ltd

107 Rundle Street, Kent Town, SA, Australia, 5067

Key Executives

Name Title Year Born
Mr. Victor Previn B.E., B.Eng Founder & Exec. Chairman 1958
Mr. Thomas H. Spurling AM, BSc (Hons), FRACI, FTSE, Ph.D. MD & Exec. Director 1962
Liam Cook Chief Financial Officer NA
Mr. Keith Byrne VP of Global Operations NA
Mark Flynn Investor Relations NA
Ms. Kate Hunt Head of Marketing NA
Dr. David Lubeck M.D. Chief Medical Officer NA
Mr. Bill Swaim Pres of Laserex IS Ellex (USA) NA
Mr. Joaquin V. Wolff Pres of Ellex iTrack 1958
Ms. Kimberley Menzies Group Financial Controller & Global Fin. Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.